Video

S. Peters provides an expert view by analysing the results of afatinib in LUX-Lung 3 and LUX-Lung 6 trials, results from the RADIANT study of adjuvant erlotinib in resected EGFR-positive NSCLC, and the results of onartuzumab plus erlotinib vs. erlotinib alone in MET Lung trial.